Metabolomics Profiling of Patients With A-β+ Ketosis-Prone Diabetes During Diabetic Ketoacidosis
Overview
Authors
Affiliations
When stable and near-normoglycemic, patients with "A-β+" ketosis-prone diabetes (KPD) manifest accelerated leucine catabolism and blunted ketone oxidation, which may underlie their proclivity to develop diabetic ketoacidosis (DKA). To understand metabolic derangements in A-β+ KPD patients during DKA, we compared serum metabolomics profiles of adults during acute hyperglycemic crises, without ( = 21) or with ( = 74) DKA, and healthy control subjects (n = 17). Based on 65 kDa GAD islet autoantibody status, C-peptide, and clinical features, 53 DKA patients were categorized as having KPD and 21 type 1 diabetes (T1D); 21 nonketotic patients were categorized as having type 2 diabetes (T2D). Patients with KPD and patients with T1D had higher counterregulatory hormones and lower insulin-to-glucagon ratio than patients with T2D and control subjects. Compared with patients withT2D and control subjects, patients with KPD and patients with T1D had lower free carnitine and higher long-chain acylcarnitines and acetylcarnitine (C2) but lower palmitoylcarnitine (C16)-to-C2 ratio; a positive relationship between C16 and C2 but negative relationship between carnitine and β-hydroxybutyrate (BOHB); higher branched-chain amino acids (BCAAs) and their ketoacids but lower ketoisocaproate (KIC)-to-Leu, ketomethylvalerate (KMV)-to-Ile, ketoisovalerate (KIV)-to-Val, isovalerylcarnitine-to-KIC+KMV, propionylcarnitine-to-KIV+KMV, KIC+KMV-to-C2, and KIC-to-BOHB ratios; and lower glutamate and 3-methylhistidine. These data suggest that during DKA, patients with KPD resemble patients with T1D in having impaired BCAA catabolism and accelerated fatty acid flux to ketones-a reversal of their distinctive BCAA metabolic defect when stable. The natural history of A-β+ KPD is marked by chronic but varying dysregulation of BCAA metabolism.
Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers.
Liu C, Chen H, Ma Y, Zhang L, Chen L, Huang J Front Endocrinol (Lausanne). 2025; 16:1501305.
PMID: 40070584 PMC: 11893406. DOI: 10.3389/fendo.2025.1501305.
Spagnolo P, Tweddell D, Cela E, Daley M, Clarson C, Rupar C Mol Med. 2024; 30(1):250.
PMID: 39707182 PMC: 11660668. DOI: 10.1186/s10020-024-01046-9.
Kubota-Mishra E, Huang X, Minard C, Astudillo M, Refaey A, Montes G Pediatr Diabetes. 2024; 2024.
PMID: 38765897 PMC: 11100136. DOI: 10.1155/2024/5907924.
Ward L, Kling S, Engvall G, Soderberg C, Kugelberg F, Green H iScience. 2024; 27(5):109794.
PMID: 38711455 PMC: 11070332. DOI: 10.1016/j.isci.2024.109794.
Plasma amino acid signatures define types of pediatric diabetes.
Tosur M, Hsu J, Deen S, Huang X, Guffey D, Uysal S Clin Nutr ESPEN. 2023; 57:21-28.
PMID: 37739658 PMC: 10518839. DOI: 10.1016/j.clnesp.2023.06.005.